HOWL vs. ALDX, TSVT, ME, FHTX, IMMP, VERU, PYXS, CDT, ACIU, and EBS
Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Aldeyra Therapeutics (ALDX), 2seventy bio (TSVT), 23andMe (ME), Foghorn Therapeutics (FHTX), Immutep (IMMP), Veru (VERU), Pyxis Oncology (PYXS), Conduit Pharmaceuticals (CDT), AC Immune (ACIU), and Emergent BioSolutions (EBS). These companies are all part of the "pharmaceutical preparations" industry.
Werewolf Therapeutics (NASDAQ:HOWL) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Werewolf Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
Aldeyra Therapeutics received 457 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. Likewise, 69.36% of users gave Aldeyra Therapeutics an outperform vote while only 62.16% of users gave Werewolf Therapeutics an outperform vote.
In the previous week, Aldeyra Therapeutics had 3 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 6 mentions for Aldeyra Therapeutics and 3 mentions for Werewolf Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.96 beat Werewolf Therapeutics' score of 0.09 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.
Werewolf Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 145.90%. Aldeyra Therapeutics has a consensus price target of $9.33, indicating a potential upside of 128.20%. Given Werewolf Therapeutics' higher probable upside, research analysts clearly believe Werewolf Therapeutics is more favorable than Aldeyra Therapeutics.
64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 21.1% of Werewolf Therapeutics shares are held by insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Aldeyra Therapeutics has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -256.33%. Aldeyra Therapeutics' return on equity of -24.69% beat Werewolf Therapeutics' return on equity.
Werewolf Therapeutics has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aldeyra Therapeutics beats Werewolf Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Werewolf Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Werewolf Therapeutics Competitors List
Related Companies and Tools
